CA2528095C - Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation - Google Patents

Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2528095C
CA2528095C CA2528095A CA2528095A CA2528095C CA 2528095 C CA2528095 C CA 2528095C CA 2528095 A CA2528095 A CA 2528095A CA 2528095 A CA2528095 A CA 2528095A CA 2528095 C CA2528095 C CA 2528095C
Authority
CA
Canada
Prior art keywords
methods
compositions
making
pathogenic microorganisms
inactivating pathogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2528095A
Other languages
English (en)
Other versions
CA2528095A1 (fr
Inventor
James R. Baker
Ted C. Annis
Tarek Hamouda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobio Corp
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Publication of CA2528095A1 publication Critical patent/CA2528095A1/fr
Application granted granted Critical
Publication of CA2528095C publication Critical patent/CA2528095C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Abstract

La présente invention a trait à des compositions de nanoémulsions à faible toxicité présentant une inactivation d'une grande variété de micro-organismes ou de prévention de maladies. Les nanoémulsions contiennent une phase aqueuse, une phase huileuse, comprenant une huile et un solvant organique, et un ou des tensioactifs. L'invention a également trait à des procédés de fabrication de nanoémulsions et d'inactivation de micro-organismes pathogènes.
CA2528095A 2003-06-04 2004-06-03 Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation Active CA2528095C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45763303P 2003-06-04 2003-06-04
US60/475,633 2003-06-04
PCT/US2004/017417 WO2005027872A2 (fr) 2003-06-04 2004-06-03 Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation

Publications (2)

Publication Number Publication Date
CA2528095A1 CA2528095A1 (fr) 2005-03-31
CA2528095C true CA2528095C (fr) 2014-10-14

Family

ID=34375188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2528095A Active CA2528095C (fr) 2003-06-04 2004-06-03 Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP1633322A2 (fr)
AU (1) AU2004273779B2 (fr)
CA (1) CA2528095C (fr)
WO (1) WO2005027872A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
CN103315954A (zh) * 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
EP1951200A2 (fr) * 2005-08-09 2008-08-06 Nanobio Corporation Compositions de nano-émulsion ayant une activité anti-inflammatoire
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2006349377B2 (en) 2005-12-01 2013-06-27 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101466355A (zh) * 2006-04-07 2009-06-24 诺瓦瓦克斯股份有限公司 具有抗细菌、抗真菌、抗酵母和/或抗病毒性质的纳米化组合物
EP2012771A4 (fr) * 2006-04-13 2010-01-27 Univ Michigan Vaccins à base d'une nanoémulsion
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
WO2008070538A2 (fr) 2006-12-01 2008-06-12 Anterios, Inc. Nanoparticules à entités amphiphiles
WO2008140594A2 (fr) 2006-12-01 2008-11-20 Anterios, Inc. Nanoparticules peptidiques et utilisations de celles-ci
EP1938801A1 (fr) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoémulsion
DE102007007698A1 (de) * 2007-02-09 2008-08-21 Exner, Heinrich, Dr. Verwendung einer hochemulgierten Silikonöl-Emulsion (HSE)zur Herstellung eines Medikamentes
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
WO2009131995A1 (fr) 2008-04-21 2009-10-29 Nanobio Corporation Vaccin antigrippal à base de nanoémulsion
US20090269394A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Methods and compositions for treating onchomycosis
US8226965B2 (en) 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
AU2009261995A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
US20100092526A1 (en) 2008-09-26 2010-04-15 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
JP2012514030A (ja) * 2008-12-31 2012-06-21 スネーヴ・ファーマ・ソリューション・リミテッド 座瘡及び皮膚障害の処置のための局所生薬製剤
WO2010140170A1 (fr) * 2009-06-05 2010-12-09 Sunev Pharma Solution Limited Micro-émulsions topiques pour le traitement de troubles rhumatismaux
AU2013213678B2 (en) * 2009-12-03 2016-06-23 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
EA024770B1 (ru) 2009-12-03 2016-10-31 Новартис Аг Способ получения вакцинного адъюванта
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506832B1 (fr) 2009-12-03 2014-02-26 Novartis AG Filtration hydrophile pendant la fabrication d'adjuvants de vaccins
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2380558B2 (fr) † 2009-12-03 2019-10-16 Novartis AG Production d'une Emulsion par arrangement de chambres d'interaction et de contre pression pour la microfluidisation
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2014206857A1 (fr) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Formulations huile-dans-l'eau de mycobacterium et utilisations associées
CN106535632A (zh) * 2014-03-21 2017-03-22 弗罗里达大学研究基金会有限公司 用纳米颗粒和/或纳米乳液配制的醛在增强植物对黄龙病菌的疾病抗性中的用途
CN104274405A (zh) * 2014-10-21 2015-01-14 河南牧翔动物药业有限公司 一种水包油型复方头孢噻呋纳米乳抗菌药物
AU2016215182B2 (en) 2015-02-06 2019-09-12 R. P. Scherer Technologies, Llc Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
WO2018039375A1 (fr) 2016-08-23 2018-03-01 Akouos, Inc. Compositions et méthodes pour traiter une déficience auditive non associée à l'âge chez un sujet humain
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
CN106924730B (zh) * 2017-02-14 2019-11-08 商丘美兰生物工程有限公司 猪伪狂犬病毒芦荟胶纳米乳佐剂灭活苗及其制备方法
JP7309720B2 (ja) * 2018-01-23 2023-07-18 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ ラウリン油を含む透明ナノエマルジョンの製造方法
EP3743037B1 (fr) * 2018-01-23 2021-10-13 Unilever IP Holdings B.V. Nanoémulsions transparentes comprenant de l'huile laurique
WO2021168362A1 (fr) 2020-02-21 2021-08-26 Akouos, Inc. Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
CN113662006B (zh) * 2021-06-30 2022-05-20 南京凯创协同纳米技术有限公司 一种可杀灭细菌灭活病毒的微纳锌的制备方法
WO2024005601A1 (fr) * 2022-06-30 2024-01-04 씨제이제일제당(주) Composition médicale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2912426B2 (ja) * 1990-06-15 1999-06-28 鐘紡株式会社 微細化エマルション組成物
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
DE60130791T2 (de) * 2000-12-27 2008-07-17 Ares Trading S.A. Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
WO2004030608A2 (fr) * 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Vaccins sous forme de nanoemulsion

Also Published As

Publication number Publication date
AU2004273779B2 (en) 2009-10-22
AU2004273779A1 (en) 2005-03-31
WO2005027872A3 (fr) 2006-03-09
EP1633322A2 (fr) 2006-03-15
WO2005027872A2 (fr) 2005-03-31
AU2004273779A2 (en) 2005-03-31
CA2528095A1 (fr) 2005-03-31

Similar Documents

Publication Publication Date Title
CA2528095C (fr) Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation
WO2008051186A3 (fr) Compositions de nano-émulsion ayant une activité anti-inflammatoire
EP2949644A3 (fr) Composés de tétracycline substituée
WO2005009943A3 (fr) Composes de tetracycline substitues
WO2006047671A3 (fr) 4-aminotetracyclines et procedes d'utilisation
WO2004098494A3 (fr) Composés, compositions et procédés
MXPA02006564A (es) Composiciones antimicrobianas y metodos de uso.
WO2004103960A3 (fr) Composes et utilisations de ces derniers
WO2005066151A3 (fr) Inhibiteurs d'histone desacetylase
EP2345637A3 (fr) Composés de tétracycline substitués en position 3, 10 et 12a
WO2007044032A3 (fr) Préparations à effet antiviral et antibactérien important
ZA200500877B (en) Antimicrobial aza-bicyclic derivatives, their compositions and uses.
WO2006099192A3 (fr) Compositions de peroxyde organique stables
EP2518079A3 (fr) Inhibiteurs du VHC/VIH et leur utilisation
WO2007005471A3 (fr) Compositions de peroxyde organique stable
WO2006114186A3 (fr) Suspoemulsions eau dans l'huile
UA88956C2 (ru) Синергическая фунгицидная комбинация действующих веществ
WO2007025098A3 (fr) Composes de triazole et preparation et utilisation de ces composes
WO2005007103A3 (fr) Utilisation de derives de parthenolide en tant qu'agents antileucemiques et cytotoxiques
WO2005035537A3 (fr) Heterocycles tricycliques substitues et leurs utilisations
WO2005051083A3 (fr) Composes molluscicides et anti-anatifes
WO2007022321A3 (fr) Indoles substitues et procedes d'utilisation de ceux-ci
TW200602295A (en) Organic compounds
WO2002080855A3 (fr) Methodes et composes permettant de reduire la toxicite ou la mort cellulaire
WO2004091513A3 (fr) Composes de la minocycline substitues par 9-aminomethyle

Legal Events

Date Code Title Description
EEER Examination request